Drug intelligence / Profile preview

SOL-512

Development stage: Preclinical
Lead developer: Sola Biosciences
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

SOL-512 is a gene therapy drug candidate developed by SOLA Biosciences. It is in preclinical development and is being investigated primarily for the treatment of cystic fibrosis, with potential applications in other congenital disorders, digestive system disorders, and respiratory diseases. The specific mechanism of action, molecular target(s), and delivery vector have not been disclosed publicly as of June 2025. The therapy represents an innovative approach to address genetic diseases through gene modification or replacement[3].

Beyond the preview

Go deeper on SOL-512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-512.

Explore the full profile